What the FDA labels say about taking them together
Everolimus and octreotide
Everolimus's FDA label (Zortress) of February 12, 2026 names octreotide in its drug interactions section; the octreotide labels PlainMeds reads (4) do not name everolimus. The everolimus label: “Coadministration of everolimus and depot octreotide increased octreotide C min by approximately 50%.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the everolimus label say about octreotide?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsCoadministration of everolimus and depot octreotide increased octreotide C min by approximately 50%.
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the octreotide label say about everolimus?
Octreotide's label (effective July 22, 2026) and its 3 other brand-application labels do not name everolimus in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Octreotide | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $2.53 per mL 100 mcg/mL vial |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once